ALDYSTRO
Live / Applied — Fourth extension granted (statement of use) (as of 05 May 2025)
What this means for you
Not registered yet, but its 18 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97368281
- Mark type
- Stylized text
- Filed
- 18 Apr 2022
- Published for opposition
- 14 Mar 2023
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 28 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 May 2025 — SOU EXTENSION 4 GRANTED
- 05 May 2025 — SOU EXTENSION 4 FILED
- 05 May 2025 — SOU TEAS EXTENSION RECEIVED
- 05 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Nov 2024 — SOU EXTENSION 3 GRANTED
- 05 Nov 2024 — SOU EXTENSION 3 FILED
- 05 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 18 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Apr 2024 — SOU EXTENSION 2 GRANTED
- 17 Apr 2024 — SOU EXTENSION 2 FILED
- 17 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 31 Oct 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Oct 2023 — SOU EXTENSION 1 GRANTED